ARQL DRUG SYMBOL IMYN IN BARONS REPORTGreen Baron Conclusion
We are fortunate to have found a biotech with overwhelming positive clinical data to support its discovery of a whole new class of bioresponse modifiers. SF-1019 appears to modulate and regulate the auto-immune system at indication with no negative side effects seen to date. This is breakthrough science and will not go unnoticed long.
The Green Baron Report recognizes the mammoth potential for SF-1019, and we believe current shareholders of IMYN made up primarily of insiders and Argyll Biotechnologies are holding out for much bigger numbers. Limited approvals outside the United States could still bring huge revenues to Immunosyn even in the current year.
IMYN stock tends to rally strongly on good news, and we are confident there is plenty to come. We suggest members pick off shares below $4 for a move to double digits over the next few months, and don’t be surprised if you hear this company’s story on your local news or talk show soon.
IF YOU WANT TO HEAR MORE GO TO BARON.COM THEN TYPE IMMUNOSYN CORPORATION IMYN
its argyll group though and argyll equities thats backing the company that has 58 percent in the company alone. the drug is developed their just waiting for a bigger outcome overseas. this st for sure can make you rich and has no side effects, all the big bio are scared to death over this company